Literature DB >> 30648477

Primary Human Osteocyte Networks in Pure and Modified Collagen Gels.

Anne Bernhardt1, Emilia Weiser1, Sophie Wolf1, Corina Vater1, Michael Gelinsky1.   

Abstract

Osteocytes play a key role in orchestrating bone homeostasis and turnover and, therefore, in vitro investigations with osteocytes are of high relevance for biomaterial and drug testing in future. In this study, collagen type I gels and collagen gels modified with biomimetically mineralized collagen were tested as three-dimensional (3D) environment for the maintenance of the osteocytic phenotype of primary human osteocytes. After cultivation in different collagen gels, cells were analyzed microscopically for the osteocytic phenotype and gene expression of osteocyte marker genes osteocalcin, podoplanin (PDPN)/E11, phosphate regulating endopeptidase homolog, X-linked (PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 (DMP-1), and sclerostin (SOST). Directly after isolation from bone tissue the cells expressed all examined osteocyte markers. After 7 days of 3D cultivation in collagen gels the osteocytic marker genes MEPE and SOST were upregulated and the other marker genes still expressed. Modification of collagen gels with biomimetically mineralized collagen and strontium-doped mineralized collagen prevented the cell-seeded gels from shrinking. Osteocyte morphology was not affected by the gel modification. However, the isolation of RNA from the mineralized gel variants was heavily impaired. Alternatively, the osteocytic differentiation of human osteoblasts in the different collagen gels was examined. Primary human osteoblasts were embedded into the gels and cultivated under osteogenic stimulation. After 14 days of cultivation, embedded osteoblasts showed osteocyte-like morphology and positive staining for DMP-1. Early osteocyte marker genes, such as PDPN/E11 and PHEX, were expressed while the expression of the osteoblast marker gene alkaline phosphatase (ALPL) increased. This ALPL upregulation was partly prevented by modification of collagen gels with mineralized collagen. Impact Statement This research focuses on the in vitro three-dimensional cultivation of primary human osteocytes instead of rodent osteocyte cell lines. Stable in vitro cultures of these regulating cells provide the opportunity to establish co- and triple cultures with osteoblasts and osteoclasts to analyze the cross talk between these cell species and to establish in vitro bone models for the testing of bioactive molecules, growth factors, drugs, and biomaterials.

Entities:  

Keywords:  collagen gel; dentin matrix protein 1; in vitro; mineralized collagen; osteocyte

Year:  2019        PMID: 30648477     DOI: 10.1089/ten.TEA.2018.0338

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  5 in total

1.  A 3D, Dynamically Loaded Hydrogel Model of the Osteochondral Unit to Study Osteocyte Mechanobiology.

Authors:  Rachel L Wilmoth; Virginia L Ferguson; Stephanie J Bryant
Journal:  Adv Healthc Mater       Date:  2020-10-19       Impact factor: 9.933

Review 2.  Design and clinical application of injectable hydrogels for musculoskeletal therapy.

Authors:  Øystein Øvrebø; Giuseppe Perale; Jonathan P Wojciechowski; Cécile Echalier; Jonathan R T Jeffers; Molly M Stevens; Håvard J Haugen; Filippo Rossi
Journal:  Bioeng Transl Med       Date:  2022-03-15

Review 3.  Osteon: Structure, Turnover, and Regeneration.

Authors:  Bei Chang; Xiaohua Liu
Journal:  Tissue Eng Part B Rev       Date:  2021-03-08       Impact factor: 7.376

Review 4.  Cell Sources for Human In vitro Bone Models.

Authors:  Sana Ansari; Keita Ito; Sandra Hofmann
Journal:  Curr Osteoporos Rep       Date:  2021-01-15       Impact factor: 5.096

5.  Effects of the Sintering Process on Nacre-Derived Hydroxyapatite Scaffolds for Bone Engineering.

Authors:  Rohaya Megat Abdul Wahab; Nurmimie Abdullah; Shahrul Hisham Zainal Ariffin; Che Azurahanim Che Abdullah; Farinawati Yazid
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.